Dyspnoea perception and susceptibility to exacerbation in COPD by Ridsdale, HA & Hurst, JR
1 
 
Dyspnoea Perception and Susceptibility to 
Exacerbation in COPD 
 
 
Heidi A Ridsdale1,2 and John R Hurst2,3,4 
1: Central and North West London NHS Foundation Trust, London, UK 
2: The Camden COPD Service 
3: UCL Respiratory, University College London, London, UK 
4: Royal Free London NHS Foundation Trust, London, UK 
 
Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous condition.  This concept has 
evolved from classic descriptions of pink puffers and blue bloaters to a more complex understanding 
of disease phenotypes.  Phenotypes are relevant because they may predict an important clinical 
outcome, or a specific underlying disease mechanism (endotype), either or both of which might 
suggest benefit from a particular intervention –‘personalised medicine’.  In addition to the 
progressive decline in lung function, symptoms and physical performance that  characterise COPD, 
(some) patients are prone to periodic deteriorations in respiratory health called exacerbations.  And 
given that exacerbations are responsible for much of the morbidity, mortality and therefore health-
care costs associated with COPD, exacerbation-susceptible patients or 'frequent exacerbators' form 
a clinically relevant phenotype.  Why does one patient get more exacerbations than another?  A 
simple clinical question, without a simple answer. 
 
To this first level of complexity in COPD – phenotypes - we must add that exacerbations themselves 
are heterogeneous events.  Assume, for a moment, that a patient is truly having an exacerbation 
(and not one of the other pathologies that can cause symptom deterioration in COPD [1]).  That 
exacerbation might be caused by acquisition of a respiratory virus, alterations in the airway bacterial 
microbiome, both or indeed neither and these are associated with different patterns of symptoms 
and inflammation [2].  Thus, if we are going to prevent and mitigate exacerbations, we need to ask 
first why is this patient a frequent exacerbator and then what type of exacerbations is this frequent 
exacerbator susceptible to?  Don’t be fooled in to thinking that prevention of exacerbations in COPD 
is easy. 
 
Some patients appear durably more susceptible to exacerbations than others, the ‘frequent 
exacerbator’ phenotype [3], and the associations of exacerbation frequency in COPD – note 
associations, not causes –are well described.  They include disease severity, female sex, and the 
presence of gastro-oesophageal reflux, all of which increase the risk of exacerbation.  Specific 
mechanisms to explain exacerbations have been harder to define – and thus the concept that 
exacerbation susceptibility is an endotype remains more challenging.  Some studies have examined 
various functions of the immune system for example [4], a plausible target, but what if the 
explanation is something much more clinical?  What if symptom perception differs in those 
susceptible to frequent exacerbations?  All those engaged with exercise interventions in COPD will 
recognise that the perception of dyspnoea for a given task varies greatly between patients [5].  Do 
frequent exacerbators simply have a greater perception of breathlessness?  A paper in this issue of 
the Journal sheds light on this area [6]. 
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Scioscia and colleagues [6] report a small experimental medicine study in which the perception of 
breathlessness and ventilatory response to hypercapnoea were assessed in 34 patients with stable 
COPD (14 frequent and 20 infrequent exacerbators), and ten healthy controls.  The bottom line is 
that there was no statistically significant difference in the ventilatory response by exacerbation 
susceptibility status (though this was diminished in COPD patients compared to controls), but there 
was a difference in breathlessness perception.  Dyspnoea perception was greater in frequent 
exacerbators compared to infrequent and, oddly, the infrequent exacerbators had a blunted 
response compared to the controls.  This is difficult work to do and we applaud the investigators for 
their effort, but the study is not without flaws.  Notably, there were clinically relevant differences in 
disease severity between the COPD groups that did not reach statistical significance because of the 
study size (50% vs. 21% GOLD Stage 2, for example).  Such differences remain an explanation for the 
reported alterations in dyspnoea perception.  Also, patients with respiratory failure, and the sorts of 
cardiac co-morbidities that are important in clinical practice were excluded. 
 
So would reducing dyspnoea perception be a good way to mitigate exacerbations of COPD?  
Perhaps.  But there is the more troubling concern that perception of breathlessness in the context of 
an exacerbation could be a good thing.  Not perceiving an exacerbation, and therefore not treating 
it, could result in greater lung damage.  We know, for example, that a greater proportion of 
unreported (untreated) exacerbations can be associated with poorer health outcomes including 
greater risk of hospitalisation [7].  However, in these studies unreported exacerbations had been 
perceived as changes in symptoms, they just hadn’t presented for therapy.  Could therebe a group of 
sub-clinical exacerbations that also contribute to progression of lung disease and which are at 
present ignored? 
 
Like all good research, this paper raises more questions than it answers.  What can we learn?  First, 
we should be noting for an individual patient how breathless they get with exercise (routinely 
measured as part of Pulmonary Rehabilitation) and asking whether results suggest that the patient 
has altered perception.  Because if they do, then intervention to affect that – learned breathing 
techniques for example – just might help, and may be more likely to help than, say, inhaled 
corticosteroids.  Better yet, why not an adequately powered trial of such an intervention in a group 
of patients with altered dyspnoea perception?  Meanwhile, in the same way that not every patient 
with COPD is the same, not every frequent exacerbator is the same, and it is likely that not every 
frequent exacerbator gets exacerbations for the same reasons.  Remember this in your next clinic: 
right intervention, right patient, right time. 
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